Roche's giredestrant combo cuts progression risk 44% in advanced breast cancer, NEJM publishes evERA data

The fair value estimate for Iovance Biotherapeutics has been raised to US$12.80 per share from US$10.00, according to Simply Wall St. The revision reflects stronger expectations for the Amtagvi launch, margin trends and upcoming data, with the revenue growth assumption shifting from 43.38% to 45.57% and the net profit margin assumption moving from 9.50% to 12.09%. H.C. Wainwright lifted its price target to US$20 from US$9, citing FY26 total revenue guidance of US$410m to US$420m tied to U.S. demand for Amtagvi and Proleukin, while Wells Fargo moved to US$18 from US$14 and Goldman Sachs pointed to an inflection in the Amtagvi launch and easing logistical challenges. Barclays flagged durability in second line lung cancer for lifileucel ahead of IOV-LUN-202 data, while UBS, which raised its target to US$7 from US$4 and remains Neutral, noted that a strong Amtagvi quarter and gross margin of 56% came alongside a 74% rally in the stock. The valuation model's future P/E multiple changed from 75.55x to 72.80x and the discount rate moved from 7.47% to 7.50%.

Genmab A/S announced that its investigational antibody-drug conjugate rinatabart sesutecan, known as Rina-S, achieved a confirmed objective response rate of 45.9% among 109 treated patients with platinum-resistant ovarian cancer in Part C of the Phase 1/2 RAINFOL-01 trial. The results, presented in a Late-Breaking Oral Session at the International Gynecologic Cancer Society Congress 2026 in Montreal, Canada, included five complete responses and a median duration of response of 12.1 months, with 51% of responders still in response at one year. The study also reported a median progression-free survival of 9.5 months, and antitumor activity was observed regardless of folate receptor alpha expression levels, including in patients with low expression and non-expressors, and regardless of prior treatment with mirvetuximab. More than half of patients, 53%, had received three or four prior lines of therapy, all had received prior bevacizumab and taxane therapy, 49.5% had received a prior PARP inhibitor, and 33% had received prior mirvetuximab soravtansine. The most common treatment-emergent adverse events were fatigue at 57.8% and low-grade gastrointestinal events including nausea at 67.9%, while serious adverse events were reported in approximately one-third of participants and treatment discontinuation due to adverse events occurred in 5.5%. Rina-S is being evaluated across four Phase 3 trials in platinum-resistant ovarian cancer, endometrial cancer, platinum-sensitive ovarian cancer maintenance, and second-line platinum-sensitive ovarian cancer, plus additional Phase 1/2 and Phase 2 studies.